However, deletion of Gsto1 in mice does not produce an observable phenotype [97] and GSTO1 deficiency in a human breast cancer cell line does not alter sensitivity to arsenic or cytotoxic cancer drugs [95] Despite these discordant findings Gsto1 expression is highly correlated with many metabolic genes, some of which are involved in AD pathways. This evidence concerns the gene GSTO1 and breast carcinoma.